MERCK KGAA Your Contact
Heather Connor
Phone +1-978-294-1660
Reicin brings extensive experience in R&D as a senior leader in biopharma
Reicin will serve as a member of the Merck Serono R&D Executive
Leadership Team
Darmstadt, Germany, April 16, 2015 - Merck Serono, the biopharmaceutical business of Merck, today announced the appointment of Alise Reicin, MD, as Senior Vice President, Head of Global Clinical Development. Dr. Reicin brings extensive research and early/late clinical development expertise to Merck Serono, including experience in Oncology and Immunology. She is an accomplished pharmaceutical executive with strong leadership ability, having served as a Vice President in various capacities across R&D at MSD (Merck Sharp & Dohme) for the last 10 years.
In her role as Head of Global Clinical Development, Reicin will oversee the Clinical Development organization, including the Clinical Development Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs. In this capacity, she will lead Merck Serono's portfolio of pipeline programs.
"We are honored to have Alise join Merck Serono," says Luciano Rossetti, Head of Global Research and Development. "Her impressive experience across diverse areas of clinical research and operations will bring significant value to our organization. She is an accomplished executive whose leadership will serve to significantly advance our clinical development efforts and our strong commitment to enhance our R&D operating
model."
Page 1 of 3
Merck KGaA www.merckserono.com Merck Serono is a business of Merck. Frankfurter Strasse 250
64293 Darmstadt
Germany
Hotline +49 6151 72-5000 www.merckgroup.com
Tel. +978-294-1660 heather.connor@emdserono.com
Reicin's experience complements the R&D strategy of Merck Serono, which focuses on the core therapeutic areas of oncology, immuno-oncology and immunology with several high-priority programs in late development, such as evofosfamide (TH-302) and avelumab (anti-PD-L1), as well as a number of promising early-stage assets.
Prior to joining Merck Serono, Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at MSD. In this capacity, she led MSD's PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US. She also managed program leaders across early and late oncology product development teams. During her tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development.
Before joining MSD, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.
Reicin has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).
Reicin will report to Luciano Rossetti, Head of Global R&D, and serve as a member of the R&D Executive Leadership Team. She will join Merck Serono on May 11, 2015, and be based in Billerica, MA.
Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis,
Page 2 of 3
infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and
Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
For more information, please visit www.merckserono.com
All Merck news releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/newsaboto register online, change your selection or discontinue this service.
Merck is a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials - and generated sales of around
€ 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation,
business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding
family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
Page 3 of 3
|
distributed by
|
